Human African Trypanosomiasis (Sleeping Sickness) Market Analysis by Capital Investment, Industry Outlook, Growth Potential

News
5 min readDec 30, 2021

--

The global human African trypanosomiasis (sleeping sickness) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 7.0% in the above-mentioned research forecast period.

Human African trypanosomiasis (HAT), usually known as sleeping sickness is a vector-borne disease affecting humans in Sub-Saharan Africa. It is caused by parasitic protists of the species Trypanosoma brucei. It’s two sub-species that can infect humans are gambiense and rhodesiense. Both types of the parasite are typically transmitted to humans via infected tsetse (genus Glossina), Tsetse is a large biting fly that dwells in affected regions. The parasites first develop in the blood, lymph and peripheral organs (stage 1) and further spread to the central nervous system (stage 2), where they cause severe neurological disorders. The diseases caused by these infections are generally fatal without treatment.

Get Full PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) at (AVAIL UP-TO 30% OFF) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-human-african-trypanosomiasis-sleeping-sickness-market

The major players covered in the human African trypanosomiasis (sleeping sickness) market are Sara Healthcare Pvt. Ltd, Bayer Pharmaceutics Company, Scinopharm Taiwan.Ltd, Micro Orgo Chem, Rusan Pharma Ltd, Sanofi-Aventis groupe among others domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Only four drugs are approved to treat HAT. However, eflornithine and pentamidine are ineffective against sleeping sickness caused by T.b. rhodesiense. Treatment with melarsoprol, the only generally effective first-line drug, required lengthy parenteral administration and can result in up to 10% mortality. Additionally, the toxicity and the upsurge in the number of patients failing to respond to melarsoprol because of drug resistance reflect the need for the discovery of new chemotherapeutic agents against HAT. To this effect, the insufficiency of current therapies for the treatment and management of trypanosomiasis, combined with both a lack of trust in conventional medical treatment and an inability of the economy to absorb the cost of pharmaceuticals, have created a growing public interest in alternative natural drugs from botanicals.

This human African trypanosomiasis (sleeping sickness) market provides details of market share, new developments and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the human African trypanosomiasis (sleeping sickness) market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Get Complete Details with TOC For Free @ https://www.databridgemarketresearch.com/toc/?dbmr=global-human-african-trypanosomiasis-sleeping-sickness-market

Human African Trypanosomiasis (Sleeping Sickness) Market Scope and Market Size

The global human African trypanosomiasis (sleeping sickness) market is segmented based on type, symptoms, treatment and diagnostic method. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with the valuable market overview and market insights to help them in making strategic decisions for the identification of core market applications.

  • Based on type, the human African trypanosomiasis (sleeping sickness) market is segmented into trypanosoma brucei gambiense (TbG) and trypanosoma brucei rhodesiense (TbR).
  • Based on symptoms, the human African trypanosomiasis (sleeping sickness) market is segmented into stage 1: fevers, headaches, itchiness, joint pains and stage 2: trouble sleeping, confusion and poor coordination.
  • Based on treatment, the human African trypanosomiasis (sleeping sickness) market is segmented into pentamidine, suramin, melarsoprol, eflornithine and nifurtimox when used in combination with eflornithine.
  • Based on diagnostic method, the human African trypanosomiasis (sleeping sickness) market is segmented into blood smear and lumbar puncture.

Global Human African Trypanosomiasis (Sleeping Sickness) Market Country Level Analysis

The human African trypanosomiasis (sleeping sickness) market is analyzed and market size insights and trends are provided by type, symptoms, treatment and diagnostic method as referenced above.

North America dominates the human African trypanosomiasis (sleeping sickness) market due to changing lifestyle and also due to rising healthcare expenditure as well as increasing availability of funds for research, huge patient population, well-developed healthcare sector coupled with increasing government support for research & development in the region.

The countries covered human African trypanosomiasis (sleeping sickness) market reports are the U.S., Canada, Mexico, Brazil, Argentina, Peru, the Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of the Middle East and Africa.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Access full Report: https://www.databridgemarketresearch.com/reports/global-human-african-trypanosomiasis-sleeping-sickness-market

Competitive Landscape and Human African Trypanosomiasis (Sleeping Sickness) Market Share Analysis

The human African trypanosomiasis (sleeping sickness) market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to the human African trypanosomiasis (sleeping sickness) market.

Top DBMR Reports:

CD20 Monoclonal Antibodies Market Analysis, Trends, Top Manufacturers, Share, Growth, Statistics, Opportunities & Forecast to 2028

Home Infusion Therapy Market Outlook | Development Factors, Latest Opportunities and Forecast 2028

Gynecological Examination Chairs Market Size, Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts to 2028

Gastroscopes Market Dynamics, Comprehensive Analysis, Business Growth, Revealing Key Drivers, Prospects and Opportunities 2028

Dermabrasion Market Size, Growth Trends, Top Players, Application Potential and Forecast to 2028

About Us:

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies ly and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others. We provide a variety of services such as market verified industry reports, technology trend analysis, Formative market research, strategic consulting, vendor analysis, production and demand analysis, consumer impact studies among many others.

Contact Us:-

Data Bridge Market research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

--

--

News
News

No responses yet